Involucrin (IVL) is a key structural protein in the epidermis, primarily expressed in the suprabasal layers of stratified squamous epithelia. It plays a critical role in the formation of the cornified cell envelope, a protective barrier essential for skin integrity and defense against environmental stressors. IVL is synthesized during terminal differentiation of keratinocytes and cross-linked by transglutaminases to other proteins (e.g., loricrin, small proline-rich proteins), contributing to epidermal resilience and permeability regulation.
IVL antibodies are immunological tools targeting this protein, widely used in dermatological research and diagnostics. They help investigate epidermal differentiation disorders, such as psoriasis, ichthyosis, and skin cancers, where IVL expression is often dysregulated. In research, IVL antibodies are employed in techniques like immunohistochemistry, Western blotting, and immunofluorescence to study keratinocyte maturation, tissue-specific protein localization, and disease mechanisms. Clinically, they aid in diagnosing skin pathologies by identifying abnormal IVL expression patterns in biopsies.
Recent studies also explore IVL's potential as a biomarker in precancerous lesions and squamous cell carcinoma. However, cross-reactivity with related proteins remains a challenge, necessitating careful validation. Overall, IVL antibodies are pivotal in advancing understanding of epidermal biology and developing targeted therapies for skin diseases.